Department of Hematology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Trends Endocrinol Metab. 2023 Dec;34(12):838-848. doi: 10.1016/j.tem.2023.09.002. Epub 2023 Sep 25.
Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide, influencing numerous regulatory axes and extrahepatic vital organs. The molecular mechanisms that lead to the progression of NAFLD remain unclear and knowledge on the pathways causing hepatocellular damage followed by lipid accumulation is limited. Recently, a number of studies have shown that mRNA N-methyladenosine (m6A) modification contributes to the progression of NAFLD. In this review, we summarize current knowledge on m6A modification in the metabolic processes associated with NAFLD and discuss the challenges of and prospects for therapeutic avenues based on m6A regulation for the treatment of liver disease.
非酒精性脂肪性肝病（NAFLD）是全球最常见的慢性肝病，影响众多调节轴和肝外重要器官。导致 NAFLD 进展的分子机制尚不清楚，导致肝细胞损伤继而脂质积累的途径知之甚少。最近，许多研究表明，mRNA N-甲基腺苷（m6A）修饰有助于 NAFLD 的进展。在这篇综述中，我们总结了 m6A 修饰在与 NAFLD 相关的代谢过程中的最新知识，并讨论了基于 m6A 调节治疗肝病的治疗途径的挑战和前景。
